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Abstract
Autophagy is a crucial metabolic pathway that sustains cellular homeostasis in health
and that can also play either a protective or a destructive role in disease. During the last
decade,  progress  made in understanding of  the molecular  basis  of  autophagy has
uncovered an exciting opportunity to target  it  for the treatment of  several  human
illnesses. In fact, there is emerging interest in autophagy-modulating and autophagy-
targeted therapy with a variety of pharmacologic agents. However, to develop effective
autophagy-targeted therapy, it is essential to identify the pharmacologic key targets in
the autophagy pathway. In this chapter, we reviewed the cases of success and pitfalls of
activating or  inhibiting autophagy attempting therapeutic  intervention of  diseases,
including cancer, neurologic disorders, and infectious diseases. In all these histopatho-
logic states, autophagy is considered as the principal cellular mechanisms of defense
and immunochemical homeostasis. In the last section of this chapter, we discuss main
directions  that  may  be  of  particular  use  in  the  future  investigations,  including  a
promissory avenue for autophagy modulation for organelle-targeting therapy through
a promotion of parallel damage in lysosomal and mitochondrial membranes.
Keywords: autophagy-targeted therapy, activation/inhibition of autophagy, triterpe-
noids, lysosomal and mitochondrial membranes
1. Introduction
The  impact  of  autophagy  in  human pathogenesis  comprises  its  critical  function  for  the
degradation and recycling of long-lived proteins, lipid droplets, protein aggregates, mature
ribosomes, glycogen, and even entire organelles such as the endoplasmic reticulum, mito-
chondria, and Golgi apparatus [1, 2]. For example, when the efficiency of mitophagy (a type
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of  autophagy  that  specifically  targets  dysfunctional  mitochondria  [2–7])  is  reduced,  the
maintenance of cellular homeostasis decreases, leading to cell aging, genomic instability, and
senescence  [4,  8,  9].  However,  the  molecular  mechanism  by  which  deficient  mitophagy
jeopardizes genomic stability are unclear [10].
To develop effective autophagy-based therapy, it has been essential to identify the pharmaco-
logic key targets in the autophagy pathway for the development of new therapeutic agents.
As discussed earlier in this book, autophagy can play either a protective or a destructive role
in disease states and thus for therapeutic purposes is valuable to identify and develop
pharmacologic agents that might activate or inhibit this cellular process [11].
We will evolve this part of the chapter to review the cases of success and pitfalls of activating
or inhibiting autophagy attempting therapeutic intervention of diseases, including cancer,
neurologic disorders, and infectious diseases. In the following sections, we discuss a few
directions that may be of particular use in future investigations. As recently proposed by our
group, the promotion of parallel damage in lysosomes and mitochondria represents a prom-
issory avenue for therapeutic autophagy targeting and aiding controlled cell death and
senescence [12, 13].
2. Autophagy-modulating drugs
During the last decade, progress made in understanding of the molecular basis of autophagy
has uncovered an exciting opportunity to target it for the treatment of human illnesses [14]. In
principle, understanding the role of autophagy in diseases has helped identify new avenues
of pharmacologic modulation of autophagy as novel therapeutic intervention. Thus, knowing
the process of autophagy targeting might facilitate the search of new drugs or concepts for the
treatment of several types of diseases whose etiology or progression is associated with
autophagy including cancer [8, 15–17], degenerative diseases 25 [18–23], and lysosomal storage
disorders [24–26].
2.1. Autophagy inhibitors
The pharmacologic inhibition targeting the early or later autophagy process has been demon-
strated to play pivotal roles in cellular outcome and may affect disease processes. Because
inhibition of autophagy by pharmacologic agents also may have some off-target effects on
cellular functions, the question of whether, for example, cell death can truly occur due to
autophagy alone remains to be clarified [11, 27]. Table 1 lists the compounds identified as
inhibitors of autophagy.
The inhibitors that target the early stage of autophagy include 3-MA, Wortmannin, and
LYS294002, all of which inhibit the class III PI3K (VSP34) and disable the formation of auto-
phagosome. The inhibitors act on the later stage of autophagy, including compounds (see
Table 1) that are capable of preventing lysosomal degradation or blocking the fusion of
autophagosomes with lysosomes. For example, the neutralization of intralysosomal pH by
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lysosomotropic agents such as Bafilomycin A1, Chloroquine (CQ), Hydroxychloroquine
(HCQ), or NH4Cl prevents the digestive activity of hydrolases, leading to inhibition of
degradative activity of autolysosomes [33, 34, 37, 44]. In their unprotonated form, CQ and HCQ
can diffuse across cell membranes to become protonated and accumulated only in acidic
organelles. Once trapped within lysosomes, they interfere with prosurvival autophagy,
resulting in controlled cell death [57–60]. This unique property has established CQ as the most
widely used drug to inhibit autophagy in vitro and in vivo. Bafilomycin A1 is a selective
vacuolar-type H+-ATPase [V-ATPase] inhibitor responsible for acidifying lysosomes and
endosomes [33, 34]. Of note Bafilomycin A1 blocks the fusion of autophagosomes with
lysosomes, which results from inhibition of ATP2A/SERCA activity independently of its effect
on intralysosomal pH [35, 61].
Compounds Autophagy signaling pathway
3-methyladenine An inhibitor of autophagic/lysosomal protein degradation [28], but not a specific
autophagy inhibitor [29] may also inhibit the activity of Phosphatidylinositol
3-kinase [30], effectively blocking the early stage of autophagy. 3-MA does not
inhibit BECN1-independent autophagy [29].
ARN5187 4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1
-yl)methyl]phenol, 1 is a lysosomotropic compound with a dual inhibitory activity
against the circadian regulator NR1D2/REV-ERBβ and autophagy [31, 32].
Bafilomycin A1 A V-ATPase inhibitor that causes an increase in lysosomal/vacuolar pH and,
ultimately, blocks fusion of autophagosomes with the vacuole; the latter may result
from inhibition of ATP2A/SERCA [33–35].
Betulinic acid A pentacyclic triterpenoid that promotes parallel damage in mitochondrial and
lysosomal compartments and, ultimately, triggers autophagy associated
cell death in human keratinocytes [12].
CA074 N-(l-3-trans-propylcarbamoyloxirane-2-carbonyl)-l-isoleucyl-l-proline is a potent
and specific inhibitor of cathepsin B in vitro [36].
Chloroquine Chloroquine and its analog Hydroxychloroquine are lysosomotropic compounds
that elevate/neutralize the lysosomal/vacuolar pH [37].
Colchicine A microtubule depolarizing agent that may block autophagosome maturation to
autolysosomes and increased LC3II protein levels [38].
Desmethyl
clomipramine
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1
-Amine, an active metabolite of clomipramine inhibits late autophagy through a
significant blockage of the degradation of autophagic cargo [39]; may induce an
increase in the steady-state levels of p62/SQSTM1 by inhibiting the autophagic
flux as opposed to an activation of the autophagic pathway [39].
E64d Inhibits papain-like cathepsin cysteine proteases and calpain-activated neutral
proteases [40]; should be used in combination with pepstatin A to inhibit lysosomal
protein degradation [29].
Eflornithine 2,5-diamino-2-(difluoromethyl)pentanoic acid, an irreversible inhibitor of ODC1
(ornithine decarboxylase 1) that blocks spermidine synthesis and ATG5 gene
expression acting as a novel autophagy inhibitor [41].
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Compounds Autophagy signaling pathway
Leupeptin An inhibitor of cysteine, serine, and threonine proteases that causes significant
inhibition of the intracellular maturation of cathepsin B, L, and H [37, 42, 43]; decreases the
degradation of short- and long-lived proteins [44]; should be used in combination with
pepstatin A and/or E-64d to block lysosomal protein degradation [29].
Lucanthone Interferes with lysosomal function and leads to the accumulation of undegraded
proteins and induces a cathepsin D-mediated apoptosis [45].
LYS294002 2-(4-morpholi-nyl)-8-phenylchromone may prevent autophagic sequestration by
inhibiting phosphatidylinositol 3-kinase activity [30].
Monensin An inhibitor of protein transport, acts as proton exchange for potassium or sodium and
inhibits autophagy by preventing the fusion of the autophagosome with
the lysosome [46].
NH4Cl Lysosomotropic compound that elevate/neutralize the lysosomal/vacuolar pH,
inhibiting the lysosomal pathway of protein degradation [37].
Nocodazole A depolymerizer of nonacetylated microtubules and impairs tubulin acetylation
but does not affect polymerized acetylated microtubules; may impair the conversion
of LC3I to LC3II but does not block the degradation of LC3II-associated
autophagosomes [47].
Pepstatin A An aspartyl protease inhibitor that can be used to partially block lysosomal
degradation [44]; should be used in combination with other inhibitors such as E-64d [29].
PES 2-Phenyl-ethynesulfonamide , a small molecule inhibitor of heat shock protein 70
(HSP70), impairs autophagy through its inhibitory effects on lysosomal functions
showing an accumulation of the precursor procathepsin L and a markedly reduced
abundance of the smaller, mature form of the enzyme [48].
Propofol May exert protective effects on neuronal cells and cardiomyocytes, in part through
the inhibition of early autophagy [49–51].
Spautin A specific and potent autophagy inhibitor 1 that promotes degradation of
the Vps34 (a phosphoinositide 3-kinase class III isoform) via inhibiting ubiquitin-
specific processing protease 10 (USP10) and USP13, two ubiquitin-specific peptidases
that target the deubiquitination of Beclin1 [52].
Thapsigargin A sarco/endoplasmic reticulum Ca (2+)-ATPase inhibitor that inhibits autophagic sequestration of
cytosolic material through the depletion of intracellular Ca2+ stores [53, 54]; also may lead to the
accumulation of mature autophagosomes by blocking autophagosome fusion with the endocytic
system by interfering with the recruitment of RAB7 [55].
Vacuolin-1 2-N-[(3-iodophenyl)methylideneamino]-6-morpholin-4-yl-4-N,4-N-diphenyl-
1,3,5-triazine-2,4-diamine, an activator of RAB5A GTPase activity that
potently and reversibly inhibits autophagosome-lysosome fusion; also
may alkalinize lysosomal pH and decrease lysosomal Ca2+ content [56].
Vinblastine A depolymerizer of both nonacetylated and acetylated microtubules that interferes
with both LC3I-LC3II conversion and LC3II-associated autophagosome
fusion with lysosomes [47].
Wortmannin An inhibitor of PI3K and PtdIns3K that blocks autophagy, but not a specific inhibitor
that prevents autophagic sequestration such as 3-methyladenine [30].
Table 1. Compounds known to inhibit autophagy.
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Other inhibitors of autophagy that impair the autolysosome formation include the antide-
pressant drug Desmethylclomipramine, the anti-schistome agent Lucanthone, Eflornithine,
Monensin, PES, Spautin, Thapsigargin, Vacuolin-1, and Vinblastine (see Table 1).
The digestive phase of autophagy may also be blocked by lessening lysosome-mediated
proteolysis such as the cysteine protease inhibitor E-64d; the aspartic protease inhibitor
Pepstatin A; the active inhibitor of cathepsin B CA074; and the cysteine, serine, and threonine
protease inhibitor Leupeptin [37, 44, 62]. Autophagosomes and lysosomes move along the
microtubules to fuse, so microtubule-disrupting agents, including taxanes, Nocodazole,
Colchicine, and Vinca alkaloids, may inhibit the fusion of autophagosomes with lysosomes
[11, 63, 64].
2.2. Autophagy activators
It is now generally believed that modulating the activity of autophagy through targeting
specific regulatory molecules in the autophagy machinery may improve clinical outcome for
diverse diseases [11, 14]. In this context, mTOR inhibitors has been considered as the most
potent activators of autophagy by playing pivotal key negative regulatory role [29]. Table 2
lists the compounds that have been identified as activators of autophagy.
Compounds Autophagy signaling pathway
10-NCP 10-(4′-N-diethylamino)butyl)-2-chlorophenoxazine that may promote potential
and safe upregulation of autophagy in neurons in an AKT-
and mTOR-independent fashion [65].
17-AAG 17-Allylamino-17-Demethoxygeldanamycin that may inhibit the HSP90 CDC37
chaperone complex activating autophagy in certain systems (e.g., neurons),
but impairs starvation-induced autophagy and mitophagy
in others by promoting the turnover of ULK1 [66].
Akti-1/2 Akt inhibitor VIII isozyme-selective Akti-1/2 can promote allosteric inhibition of
AKT1 and AKT2 and activates autophagy in B-cell lymphoma [67].
AUTEN-67 An inhibitor of MTMR14, a myotubularin-related phosphatase that may antagonize
the formation of autophagic membrane [68].
AZD8055 5-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3- d]pyrimidin-7-yl]-2-methoxyphenyl
methanol that may inhibit both mTORC1 and mTORC2 [69].
Everolimus An inhibitor of mTORC1 that induces both autophagy and apoptosis in B-cell lymphoma
primary cultures [67].
KU-0063794 A specific mTOR inhibitor that may bind the catalytic site and activates autophagy [70, 71].
MLN4924 A small molecule inhibitor of NEDD8 activating enzyme (NAE) [72] that triggers
autophagy through the blockage of mTOR signals via DEPTOR as well as the HIF1A-
DDIT4/REDD1-TSC1/2 axis [73] as a result of inactivation
of cullin-RING ligases [74].
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Compounds Autophagy signaling pathway
Oleanolic acid A pentacyclic triterpenoid that promotes damage in mitochondrial
compartments, and ultimately, activates prosurvival autophagy in human
keratinocytes [12].
NAADP-AM Nicotinic acid adenine dinucleotide phosphate (NAADP) can mobilize
Ca2+ from acidic Ca2+ stores through lysosomal
two-pore channels (TPCs) in primary cultured rat astrocytes and present evidence
that NAADP-evoked Ca2+ signals regulate autophagy [75].
NVP-BEZ235 NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative that can inhibit
the activity of target proteins in the PI3K/AKT/mTOR cascade and
activates autophagy in human gliomas [76, 77].
PMI Is a pharmacological P62-mediated mitophagy inducer (PMI) that activates
mitophagy without recruiting Parkin or collapsing the mitochondrial
membrane potential [78].
PP242 2-(4-amino-1-isopropyl-1H- pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol is a
ATP-competitive inhibitor of mTORC1 and mTORC2 [79, 80]; should be more effective mTORC1
inhibitor than rapamycin [81].
PP30 3-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-N-(4,5-dihydrothiazol-2-yl)
benzamide is a ATP-competitive inhibitor of mTORC1 and mTORC2 [81].
Rapamycin Binds to FKBP1A/FKBP12 and inhibits mTORC1; the complex binds to the FRB domain
of mTOR and limits its interaction with RPTOR, thus inducing autophagy,
but only providing partial mTORC1 inhibition [82].
Resveratrol A natural polyphenol that affects many proteins [83] via both AMPK activation
and JNK-mediated p62/SQSTM1 expression activates autophagy [84, 85].
Ridaforolimus Binds to and inhibits the mammalian target of Rapamycin (mTOR), which may
result in cell cycle arrest and, consequently, the inhibition of tumor cell growth
and proliferation.
RSVAs Synthetic small-molecule analogs of resveratrol that potently activate
AMPK and induce autophagy [86].
Saikosaponin-d A natural small-molecule inhibitor of ATP2A/SERCA that induces autophagy
via direct inhibition of sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
(SERCA), leading to the increase of intracellular calcium ion levels and
activating the Ca2+/calmodulin-dependent kinase kinase-b (CaMKKβ)/AMPK
signaling cascade [87].
Tat-Beclin 1 A cell penetrating peptide that potently induces autophagy [88, 89].
Temsirolimus Is Rapamycin ester analog CCI-779 with better stability and pharmacological
properties compared to rapamycin that activates autophagy in neurons in
Alzheimer's disease [90–92].
TMS Trans-3,5,4-trimethoxystilbene upregulates the expression of the transient receptor potential
canonical channel 4 (TRPC4), resulting in mTOR inhibition and autophagy activation [93].
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Compounds Autophagy signaling pathway
Torin1 1-[4-(4-propanoylpiperazin-1-yl)- 3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo
[h][1, 6]naphthyridin-2-one, a catalytic mTORC1 and mTORC2
inhibitor that induces autophagy [94].
Trehalose mTOR-independent, autophagic enhancer that may be relevant for the treatment of
different neurodegenerative diseases [20, 95, 96].
Tunicamycin A glycosylation inhibitor that induces autophagy due to endoplasmic reticulum
stress [97].
WYE-125132 1-[4-[1-(1,4-dioxaspiro[4.5]decan- 8-yl)-4-(8-oxa-3- azabicyclo[3.2.1]octan-3-yl)pyrazolo
[3,4- d]pyrimidin-6-yl]phenyl]-3-methylurea is an ATP-competitive and
specific inhibitor of mTORC1 and mTORC2 [98].
Table 2. Compounds known to activate autophagy.
There are several other agents that negatively regulate autophagy, such as inositol 1,4,5-
trisphosphate (IP3), epidermal growth factor receptor (EGFR), Bcl-2, and Bcl-xl. The mTORC1
inhibitor Rapamycin and its analogs Temsirolimus (CCI-79, Torisel), Everolimus (RAD001,
Afinitor), and Ridaforolimus (AP-23573, Deferolimus, MK-8669) are strong inducers of
autophagy [14], as are the ATP-competitive inhibitors of mTOR such as Torin 1 [94], PP242 [79,
80], PP30 [81] and AZD8055 [69], and WYE-125132 [98], but their autophagy-inducing efficacy
has not been well documented [11]. Other autophagic enhancers that induces autophagy via
a mTOR-independent pathway, include AUTEN-67 [68], 10-NCP [65], PMI [78], Resveratrol
[84, 85], Trehalose [20, 95, 96], and Tunicamycin [97].
3. Modulation of autophagy as a cancer therapy
The human cancer represents a significant worldwide public health problem considered as the
main cause of death [99]. Its worldwide incidence is expected to show more than 21 thousand
million new cases in 2030 [100]. To deal with such increased incidence, 47,608 clinical 15 trials
have been currently carried out according to Clinical Trials.Gov [101]. Therapeutic targeting of
the autophagy pathway as a new anticancer strategy has been under extensive investigation
[11, 64, 102, 103]. Several data indicate that prosurvival autophagy confers a tumor growth
advantage through the supplementation of required nutrition of growth, and thus it represents
a novel therapeutic target [46, 104]. Actually, autophagy may represent a major impediment
to successful cancer therapy by radiation, drugs (e.g., Doxorubicin, Temozolomide, and
Etoposide), histone deaceltylase inhibitors, Arsenic trioxide, TNF-alpha, IFN-gamma, Imati-
nib, and Rapamycin and the anti-estrogen hormonal therapy Tamoxifen as reviewed [46, 104,
105]. Dalby and colleagues propose that inhibitors of autophagy may either enhance the
efficacy of anti-tumor therapy or promote cell death not only in primary cancer types but also
in advanced-stage cancers and metastatic tumors that are considered drug resistant or
apoptosis resistant, such as chemotherapy-resistant cancer [105]. However, depending on the
context, such as tumor type or stage, the autophagy-enhancing agents believed to induce a
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type II programmed cell death mechanism through an extensive autophagic degradation of
intracellular content may also elicit beneficial effects in the treatment of cancer [105]. Both the
approaches, inhibition of either the prosurvival or induction of prodeath mechanism of
autophagy, will be discussed further.
3.1. Use of autophagy activators in cancer treatment
Several evidence have suggested that increased autophagy may kill cells. However, the
weakness of many studies has been that the demonstration of autophagy after a cytotoxic
treatment does not prove that autophagy contributed to cell death, only that it was associated
with it [11]. It is equally plausible that increased autophagy in these settings was more a failed
effort to maintain cell survival than triggering per se cell death. If autophagy would act more
definitively as a prodeath cell role than a prosurvival one, its inhibition would have to increase
survival. In fact, most studies have showed that a cell death had been counterbalanced by an
autophagic salvage response rather than demonstrate a causative role for autophagy in the
promotion of cell death [106, 107]. Nonetheless, induction of autophagy-associated cell death
has been suggested as a potential strategy to eradicate human cancers [108]. In fact, several
anticancer drugs have been reported to kill tumor cells through autophagy-mediated mecha-
nisms, include Photodynamic Therapy, Cisplatin, 5-Fluoroacil, Etoposide, Imatinib, and
Paclitaxel, as reviewed [109].
Rapamycin and its more soluble analog Temsirolimus trigger autophagy, as does KU-63794,
whose selective mTOR inhibition has been attributed to its antitumor mechanism regardless
apoptosis induction [110–112] in which the disruption of the PI3K/Akt signaling pathway
might greatly enhance the effectiveness of mTOR inhibitors [110]. Likewise, the inhibitory
effect of the mTOR inhibitor Everolimus on acute lymphoblastic leukemia was associated with
autophagy activation [113]. The combination of Temsirolimus, an mTOR inhibitor, and HCQ,
an autophagy inhibitor, augments cell death in preclinical models [114].
The ATP-competitive inhibitors of mTORC1/mTORC2, WYE-125132 [98], and AZD8055 [69]
have demonstrable anticancer activity by growth inhibition, and potentially autophagy both
in vitro and in vivo. In case of rapamycin-resistant T37/46 phosphorylation sites on 4E-BP1,
AZD8055 may fully inhibit mTOR [69]. AZD8055 is currently in Phase I clinical trials as an
antitumor agent (NCT00973076, NCT01316809, NCT00999882 and NCT00731263). The
tyrosine kinase inhibitor Dasatinib (BMS-354825) has been reported to enhance the antiglioma
effect of Temozolomide through triggering significant decrease in cell proliferation while
simultaneously increasing autophagy, and this action can be antagonized by the autophagy
inhibitor 3-MA [115].
Other types of drugs possessing an autophagy-inducing effect have also found their potential
application in cancer treatment (see Table 3). For instance, autophagy-associated cell death
may contribute to the anticancer actions of the histone deacetylase (HDAC) inhibitor suber-
oylanilide hydroxamic acid (Vorinostat) [116–118]. Vorinostat may induce autophagy through
downregulation of Akt/mTOR signaling and induction of ER stress response, whose biological
effects might be antagonized by the autophagy inhibitor 3-MA [117]. Coadministration of
Vorinostat and a poly (ADP-ribose) polymerase (PARP) inhibitor Olaparib synergistically
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inhibits the growth of triple-negative breast cancer cells through increased apoptotic and
autophagy-associated cell death [119]. In Tamoxifen-resistant MCF-7 breast cancer cells the
HDAC inhibitor MHY218 induces apoptosis or autophagy-related cell death [120]. The
estrogen receptor antagonist Raloxifene induces autophagy via the activation of AMPK by
sensing decreases in ATP, leading to a nonapoptotic autophagy-associated cell death in breast
cancer [121]. However, it has been proposed that autophagy is sterol-dependent and is
associated with cell survival rather than cytotoxicity [122]. The natural products Resveratrol
[84], triterpenoids Ursolic acid [123–125], and Saponin [126] promote cancer cell death
associated with activation of autophagy. It is conceivable that some autophagy-inducing agents
may also be useful in cancer therapies because of their ability to trigger autophagy-associated
cell death [11, 113, 115]. The same attention given to inhibitors of autophagy should be given
to autophagy-inducing or autophagy-enhancing agents [114, 127–131].
Cancer Type Identifier Study Phase Status
Renal cell
cancer
NCT00830895  Everolimus for nonclear cell renal cell carcinoma (RCC) II 1  [132]
NCT01090466  Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus
as first-line therapy to treat patients with locally
advanced and/or metastatic transitional cell cancer
of the urothelium
I/II 1
Prostate
cancer
NCT01313559  Pasireotide (SOM230) with or without Everolimus to
treat patients with hormone-resistant chemotherapy
naive prostate cancer
II 1
NCT00574769  Docetaxel with Everolimus and Bevacizumab in men
with advanced prostate cancer
I/II 1
NCT02339168  Enzalutamide and Metformin Hydrochloride to treat
patients with hormone-resistant prostate cancer
I 2
NCT01748500  Pantoprazole and Docetaxel for men with metastatic
castration-resistant prostate cancer
II 2
NCT01497925  ADIPEG 20 and Docetaxel in solid tumors with emphasis on
prostate cancer and nonsmall cell lung cancer
I 2
Breast cancer NCT00411788  Rapamycin and Trastuzumab for patients with HER-2
receptor positive metastatic breast cancer
II 3
NCT01111825  Temsirolimus and Neratinib for the treatment of patients
with metastatic HER2-amplified or triple negative
breast cancer
I/II 2
NCT00736970  Ridaforolimus in combination with Trastuzuma in patients
with metastatic, HER2-positive breast cancer who
have developed resistance to Trastuzumab.
III 1  [133]
NCT01605396  Ridaforolimus and Exemestane, compared with
Ridaforolimus, Dalotuzumab and Exemestane to
II 2
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Cancer Type Identifier Study Phase Status
treat breast cancer
NCT01234857  Ridaforolimus in combination with Dalotuzumab
compared to the standard of care treatment
in estrogen receptor positive
breast cancer patients
II 1
Nonsmall cell
lung cancer
NCT00079235  Temsirolimus to treat patients with stage III-B
(with pleural effusion) or stage IV nonsmall cell
lung cancer
II 1
NCT00923273  Sirolimus and Pemetrexed to treat nonsmall cell lung cancer I/II 1
Small cell
lung cancer
NCT00374140  Everolimus in previously treated small cell lung cancer II 1
NCT01079481  Combination anticancer therapy of Everolimus and
Paclitaxel for relapsed or refractory small cell
lung cancer
I/II 1
Pancreatic
cancer
NCT01648465  Everolimus to treat newly diagnosed patients with advanced
gastrointestinal neuroendocrine tumors
II 4
NCT01537107  Sirolimus and Vismodegib to treat patients with solid
tumors or pancreatic cancer that is metastatic
or cannot be removed by surgery
I 5
Glioblastoma NCT00329719  Temsirolimus and Sorafenib to treat patients with recurrent
glioblastoma
I/II 1
NCT01062399  Everolimus, Temozolomide, and Radiation therapy to treat
patients with newly diagnosed glioblastoma multiforme
I/II 2
NCT01956734  Virus DNX2401 and Temozolomide to treat recurrent
glioblastoma
I 2
Colorectal
cancer
NCT00522665  Second-line therapy with Irinotecan, Cetuximab,
and Everolimus to treat colorectal cancer
I/II 1
NCT01154335  Everolimus and Linsitinib to treat patients with refractory
metastatic colorectal cancer
I 1  [134]
Chronic
myeloid
leukemia
NCT01188889  Everolimus to treat chronic phase chronic myeloid leukemia
with persistent molecular disease.
I/II 6
Chronic
lymphocytic
leukemia
NCT00935792  Everolimus and Alemtuzumab to treat patients with recurrent
chronic lymphocytic leukemia or small lymphocytic
lymphoma
I/II 1
Advanced
solid
tumor
NCT00849550  Everolimus in combination with current standard treatment
of XELOX-A (Bevacizumab, Oxaliplatin, Capecitabine)
to treat advanced solid tumors
I 1
NCT01020305  Temsirolimus to reverse androgen insensitivity for I/II 1
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Cancer Type Identifier Study Phase Status
castration-resistant prostate cancer
NCT00657982  Everolimus in a neoadjuvant setting in men with
intermediate or high risk prostate cancer
II 4
NCT01155258  Temsirolimus and Vinorelbine Ditartrate to treat patients
with unresectable or metastatic solid tumors
I 2
NCT01295632  Ridaforolimus with MK-2206 or MK-0752 for participants
with advanced cancer
I 1  [135]
NCT01169532  Ridaforolimus and the HDAC inhibitor Vorinostat to
treat patients with advanced cancer
I 1  [136]
NCT00781846  Ridaforolimus in combination with Bevacizumab for
patients with advanced cancers
I 1  [137]
Endometrial
carcinoma
NCT00739830  Ridaforolimus in advanced endometrial carcinoma II 1  [138]
Multiple
myeloma
NCT00693433  Temsirolimus and Dexamethasone to treat patients with
recurrent or refractory multiple myeloma
I 1
NCT00398515  Temsirolimus and Lenalidomide to treat patients with
previously treated multiple myeloma
I 1
NCT00918333  Everolimus and Panobinostat to treat patients with
recurrent multiple myeloma, non-Hodgkin lymphoma, or
Hodgkin lymphoma
I/II 2
NCT00474929  Everolimus and Sorafenib to treat patients with
relapsed or refractory lymphoma or multiple myeloma
I/II 2
Ovarian
cancer
NCT01460979  Temsirolimus to treat ovarian cancer of women who
progressed during previous platinum chemotherapy
or within 6 months after therapy or advanced
endometrial carcinoma
II 1
NCT00982631  Temsirolimus and Pegylated Liposomal Doxorubicin to
treat advanced or recurrent breast, endometrial
and ovarian cancer
I 3
NCT01196429  Temsirolimus, Carboplatin, and Paclitaxel as first-line
therapy to treat patients with newly diagnosed
stage III–IV clear cell ovarian cancer
II 1
NCT01010126  Temsirolimus and Bevacizumab to treat advanced endometrial,
ovarian, liver, carcinoid, or islet cell cancer
II 2
NCT01031381  Everolimus and Bevacizumab to treat recurrent ovarian,
peritoneal, and fallopian tube cancer
II 1
NCT01281514  Everolimus and Carboplatin, Pegylated Liposomal Doxorubicin
Hydrochloride to treat patients with relapsed ovarian
I 4
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Cancer Type Identifier Study Phase Status
epithelial, fallopian tube, or peritoneal cavity cancer
Melanoma NCT01166126  Temsirolimus and AZD 6244 to treat naive with BRAF
mutant unresectable stage IV
II 1
NCT01014351  Everolimus with Paclitaxel and Carboplatin to treat
metastatic melanoma
II 1
NCT01092728  Dasatinib to treat acral lentiginous, mucosal, or chronic
sun-damaged melanoma
II 1
Sarcoma NCT00112372  Ridaforolimus to treat patients with refractory or advanced
malignancies and sarcomas
I/II 1  [139]
NCT00093080  Ridaforolimus to treat patients with
advanced sarcoma
II 1
1 Completed or terminated; 2 Active, not recruiting; 3 Unknown; 4 Recruiting; 5 Suspended; 6 Withdrawn.
Table 3. Clinical trials of the effects of autophagy activators on human cancers.
3.2. Use of autophagy inhibitors in cancer treatment
Autophagy confers stress tolerance that enables tumor cells to maintain metabolic homeostasis
and the adaptation to hypoxic, nutrient-limiting, and metabolically stressed environments as
well as resistance to therapy-induced stress, such as chemotherapy or radiotherapy [11, 64,
105]. Since autophagy activation confers an advantage to tumor growth, it would be one of the
hallmarks of tumor progression [140]. For example, K-RasV12 transforming malignant cells are
capable of evading metabolic stress and cell death through activation of autophagy cascades.
In an attempt to overcome this advantage of tumor behavior, the treatment with autophagy
inhibitors Bafilomycin A1 or 3-MA successfully decreases the growth of human breast
epithelial cells in vitro [141]. Also, targeting autophagy inhibition using CQ suppressed growth
and tumorigenicity of K-Ras mutation tumor cells leading to prolonged survival in pancreatic
cancer xenografts and genetic mouse models [142]. These preclinical results suggest that
autophagy might be exploited as a new therapeutic target in the setting of tumors driven by
oncogenic RAS, which may improve clinical outcome of the patients with RAS-driven tumors,
such as pancreatic cancer and malignant melanoma; however, recently reported KRAS-driven
tumor lines may not require autophagy for growth [143]. By profiling 47 cell lines with
pharmacological and genetic loss-of-function tools, Eng and colleagues suggested that KRAS
mutation status would not predict the sensitivity of cancer cells to autophagy inhibition with
CQ [143]. Accordingly, oncogenic B-RAF signaling in melanoma impairs the therapeutic
advantage of autophagy inhibition [144].
Despite this controversial relation regarding the activation of MAPK pathway and the
prediction of the efficacy of autophagy inhibition, the pharmacologic inhibition targeting the
early or late autophagy process may increase controlled cell death of several other human
tumors during chemotherapy aiding improved clinical outcomes [59, 102, 109]. The therapeutic
modulation of autophagy for cancer treatment has been supported by preclinical models in
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which inhibition of autophagy restored chemosensitivity and enhanced tumor cell death [64].
For example, CQ and its analog HCQ given in combination with chemotherapy suppressed
tumor growth and triggered cell death to a greater extent than did chemotherapy alone, both
in vitro and in vivo as reviewed [64].
Moreover, suppression of autophagy via use of chemical inhibitors of autophagy such as 3-
MA can sensitize tumor cells to the effects of chemotherapeutic drugs [11, 14], 5-Fluorouracil
[128, 145], TNF-a [146], proteasome inhibitors [147], and Src family kinase (SFK) inhibitor
Saracatinib [148].
The sensitizing effects of inhibiting autophagy on the antitumor efficacy of chemotherapeu-
tic agents have been recapitulated in preclinical models of Myc-induced lymphoma [67,
149], colon cancer [45, 59, 127, 128, 131, 145, 150–153], ovarian cancer [154], breast cancer [31,
32, 155, 156] hepatocellular cancer [157], prostate cancer [148, 156], bladder cancer [156],
melanoma [114], and glioma [152, 158]. Preclinical evidence reveals the efficacy of CQ to
inhibit the genesis and self-renewal of cancer stem cells (CSC) and underlines the impact of
this “old drug” as repurposing strategy to open a new CSC-targeted chemoprevention era
[153].
Several clinical trials that have been conducted or are in progress have shown favorable effects
of CQ as a novel antitumor drug as reviewed [159, 160]. Autophagy inhibition may contribute
to the anticancer actions of the histone deacetylase (HDAC) inhibitor Vorinostat [127, 130, 136].
Table 4 compiles recent clinical trials therapeutic targeting autophagy inhibition.
Cancer Type Identifier  Study Phase Status
Renal cell
cancer
NCT01144169  Hydroxychloroquine before surgery in
patients with primary renal cell carcinoma
I 1
NCT01480154  Akt Inhibitor MK2206 and Hydroxychloroquine to
treat advanced solid tumors, melanoma,
prostate, or kidney cancer
I 2
NCT01510119 Everolimus and Hydroxychloroquine to
treat renal cell carcinoma
I/II 4
Prostate
cancer
NCT00726596 Hydroxychloroquine to treat patients with
rising PSA levels after local therapy for
prostate cancer
II 2
NCT00786682 Docetaxel and Hydroxychloroquine to treat
metastatic prostate cancer
II 1
NCT01480154 Akt Inhibitor MK2206 and Hydroxychloroquine to treat
advanced solid tumors, melanoma, prostate,
or kidney cancer
I 2
NCT01828476 Navitoclax and Abiraterone with or without
Hydroxychloroquine to treat progressive
metastatic castrate refractory prostate cancer
II 1
Breast cancer NCT01292408 Hydrochloroquine to treat breast cancer patients II 3
NCT00765765 Hydroxychloroquine and Ixabepilone to treat
metastatic breast cancer
I/II 1
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Cancer Type Identifier  Study Phase Status
NCT01023477 Chloroquine to treat ductal carcinoma in situ I/II 4
NCT02333890 Chloroquine to treat breast cancer II 4
Non–small
cell lung
cancer
NCT00977470 Erlotinib with or without Hydroxychloroquine
in chemo-naive advanced NSCLC and (EGFR) mutations
II 2
NCT00809237 Hydroxychloroquine and Gefitinib to treat lung cancer I/II 3
NCT00933803 Hydroxychloroquine, Carboplatin, Paclitaxel, and
Bevacizumab to treat recurrent advanced
non-small cell lung cancer
I/II 1
NCT01649947 Hydroxychloroquine, Carboplatin, Paclitaxel, and
Bevacizumab to treat advanced/recurrent nonsmall
cell lung cancer
II 4
NCT00728845 Hydroxychloroquine, Carboplatin, Paclitaxel, and
Bevacizumab to treat recurrent advanced non–small
cell lung cancer
I/II 1
Small cell
lung cancer
NCT00969306 Chloroquine to treat stage IV small cell lung cancer I 4
Pancreatic
cancer
NCT01273805 Hydroxychloroquine to treat patients with metastatic
pancreatic cancer
II 2
NCT01128296 Study of presurgery Gemcitabine and Hydroxychloroquine
to treat stage IIB or III adenocarcinoma
of the pancreas
I/II 2
NCT01506973 Hydroxychloroquine in combination with Gemcitabine/
Abraxane to inhibit autophagy in pancreatic
cancer
I/II 4
NCT01978184 Gemcitabine and Abraxane with or without
Hydroxychloroquine
II 4
Glioblastoma NCT00486603 Hydroxychloroquine, radiation therapy, and
Temozolomide to treat patients with newly
diagnosed glioblastoma multiforme
I/II 1  [161]
NCT00224978 Chloroquine to treat glioblastoma multiforme III 1  [162]
NCT02432417 Chloroquine and chemoradiation to treat glioblastoma II 5
NCT02378532 Chloroquine and Chemoradiation to treat glioblastoma I 5
Colorectal
cancer
NCT01206530 FOLFOX, Bevacizumab and Hydroxychloroquine to
treat colorectal cancer
I/II 4
NCT01006369 Hydroxychloroquine, Capecitabine, Oxaliplatin,
and Bevacizumab to treat metastatic
colorectal cancer
II 6
NCT02316340 Vorinostat and Hydroxychloroquine versus Regorafenib
to treat colorectal cancer
II 4
Chronic
myeloid
leukemia
NCT01227135 Imatinib Mesylate with or without Hydroxychloroquine
to treat patients with chronic myeloid leukemia
II 3
NCT00771056 Hydroxychloroquine in untreated B-CLL Patients II 6
Advanced
solid tumor
NCT00813423 Sunitinib Malate and Hydroxychloroquine to
treat patients with advanced solid tumors
I 2
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Cancer Type Identifier  Study Phase Status
that have not responded to chemotherapy
NCT00714181 Hydroxychloroquine and Temozolomide to treat
patients with metastatic or unresectable
solid tumors
I 1
NCT00909831 Hydroxychloroquine and Temsirolimus to treat
patients with metastatic solid tumors
that have not responded to treatment
I 2
NCT01023737 Hydroxychloroquine and with histone deacetylase
(HDAC) inhibitor Vorinostat in patients with
advanced solid tumors
I 4
NCT01266057 Sirolimus or Vorinostat and Hydroxychloroquine
in advanced solid tumors
I 4
Multiple
myeloma
NCT00568880 Hydroxychloroquine and Bortezomib to treat
patients with relapsed or refractory
multiple myeloma
I/II 3
NCT01689987 Hydroxychloroquine, Cyclophosphamide, Dexamethasone,
and Sirolimus to treat patients with relapsed
or refractory multiple myeloma
I 2
NCT01438177 Chloroquine and VELCADE and Cyclophosphamide to
treat relapsed and refractory multiple myeloma
II 1
Melanoma NCT00962845 Hydroxychloroquine to treat patients with stage
III or stage IV melanoma that can be removed
by surgery
I 2
NCT01480154 Akt Inhibitor MK2206 and Hydroxychloroquine to
treat patients with advanced solid tumors, melanoma,
prostate, or kidney cancer
I 2
NCT02257424 Dabrafenib, Trametinib and Hydroxychloroquine in
patients with advanced BRAF mutant melanoma
I/II 4
1 Completed or terminated; 2 Active, not recruiting; 3 Unknown; 4 Recruiting; 5 Not yet recruiting; 6 suspended.
Table 4. Clinical trials of the effects of autophagy inhibitors on human cancers.
4. Therapeutic effects of autophagy modulators on cardiovascular diseases
Autophagy plays a dichotomous role on many cardiac pathologic states in which it may exert
both protective and detrimental effects through context-dependent mechanisms. As a
protective mechanism, autophagy closely protects the heart from myocardial ischemia-
reperfusion (I/R) and attenuates cardiac remodeling after myocardial infarction [49, 163]. In
fact, as demonstrated in ischemia-reperfusion-induced heart injury, Parkin-mediated
mitophagy showed a protective role against the cell death of cardiomyocytes [164]. Moreover,
recent evidence indicates that basal levels of autophagy are required for the maintenance of
normal cardiovascular function and morphology [165]. However, by contrast, excessive levels
of autophagy—or perhaps distinct forms of autophagic flux—contribute to several types of
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cardiomyopathy by functioning as a controlled cell death pathway [165, 166]. In line with these
findings, the selection of activators or inhibitors of autophagy for prevention or treatment of
cardiovascular diseases will be complicated. Nevertheless, in practice successful therapeutic
approaches that regulate autophagy have been reported recently, suggesting that the
autophagic machinery may be properly manipulated to treat heart failure or to prevent rupture
of atherosclerotic plaques and sudden death [165, 166]. Whereas there have been no clinical
data reporting the efficacy of pharmacologic modulation of autophagy in cardiac diseases, as
reviewed in 2011, nine patents have disclosed the pharmacologic modulation of autophagy as
a new therapeutic strategy against cardiovascular diseases [166]. In this section, we will review
the fundamental use of autophagy modulators on heart diseases, whose biological effects have
been identified through both in vitro and in vivo models.
5. Use of autophagy inhibitors in treatment of heart disease
Pharmacologic suppression of autophagy pathway comprises potential new targets for
treating cardiac disorders [11]. In vitro and in vivo studies demonstrated that the inhibitor of
histone deacetylases Trichostatin A may attenuate both load- and agonist-induced hypertro-
phic growth and abolish the associated activation of autophagy, reducing pathologic cardiac
remodeling during severe pressure overload [167]. Through negative modulation of early stage
of autophagy process by inhibiting the expression of Beclin-1 induced by myocardial I/R injury
parallel to phosphorylation of mTOR, Propofol reduces autophagy-associated cell death
induced by the myocardial I/R injury [49]. Although these strategies for suppressing the
excessive activation of autophagy for treating cardiac disorders are in theory promising, a
comprehensive view of myocardial autophagy will be obligatory to avoid disrupting homeo-
static mechanisms [166]. Thus, although the major challenges remain, patients with heart
disease are likely to benefit from these efforts.
In other situations, such as in response to stress, activation rather than suppressing autophagy
might be beneficial, since it increases the clearance of misfolded and other harmful proteins.
In fact, recent reports had established a requirement for autophagy for cardioprotection in
rodent models mediated by a variety of agents including the adenosine A1 receptor agonist
Chlorocyclopentyladenosine, Sulfaphenazole, and ischemic preconditioning [168]. On the fate
of ischemic-reperfused cardiomyocytes, autophagy plays a protective role [169, 170].
The development of a pharmacological agent to salvage myocardium after an ischemic insult
has been explored. For example, attempting to enhance the heart’s tolerance to ischemia-
reperfusion through inducing autophagy, the antimicrobial agent Sulfaphenazole might be
used [163]. Likewise, chloramphenicol succinate has been shown to activate autophagy and
reduce myocardial damage during I/R [169, 170]. In the case of regression of established
increase in myocyte cell size (i.e., cardiac hypertrophy) induced by ascending aortic constric-
tion (i.e., pressure overload), the administration of Rapamycin, a mTOR inhibitor, may
improve cardiac function [171, 172]. In line with this finding, animal studies suggest that mTOR
inhibition attenuates cardiac allograft remodeling secondary to downregulation of mTOR
Autophagy in Current Trends in Cellular Physiology and Pathology364
downstream targets and increased autophagy. To increase the paucity of data regarding effect
of Sirolimus, a mTOR inhibitor, on human heart remodeling, a current clinical trial Phase 1
has been conducted (NCT01889992).
Macrophages play a central role in atherosclerotic plaque destabilization, leading to acute
coronary syndromes and sudden death, and therefore their clearance from atherosclerotic
plaques through autophagy has been suggested as an attractive therapeutic strategy for
atherosclerosis [173]. In line with these findings, the stent-based delivery of Everolimus was
shown to selectively clear macrophages from atherosclerotic plaques in rabbits by activating
autophagy without altering smooth muscle cells [174]. As suggested recently, mTOR inhibition
represents a promising strategy for stabilization of atherosclerotic plaques [175], as this also
prevents adverse left ventricular remodeling and limits infarct size following myocardial
infarction [176]. Though the benefits afforded by autophagic activation depend on cardiac
pathologic states, vigilance for extra-cardiac effects may be critical [166].
6. Use of autophagy modulators for neurologic disorders
In contrast to other cell types, neurons for being nondividing cells are particularly sensitive to
changes in autophagic degradation [177]. As most neurons must survive for the lifetime of the
organism, maintenance of organelle function and clearance of aberrant, misfolded, and
aggregate proteins are critical processes regulated by autophagy [19]. In fact, many aggregate-
prone forms of such proteins, including tau [178], α-synuclein [179, 180], mutant huntingtin
[181], and mutant ataxin 3 [178] have a higher dependency on autophagy for their clearance.
While autophagy clears these aggregate-prone proteins, upregulation of autophagy may also
contribute to amyloid-β pathology [182], as autophagic vacuoles may represent one site of
amyloid-β generation. The intracellular accumulation of these aggregate proteins are features
of many late-onset neurodegenerative diseases, including Alzheimer’s disease (AD), Parkin-
son’s disease (PD), tauopathies, and polyglutamine expansion diseases—such as Huntington’s
disease (HD) and various spinocerebellar ataxias (SCAs) [183]. Currently, there are no effective
therapeutic strategies capable of attenuating or preventing the neurodegeneration resulting
from these diseases in humans.
Autophagy has been considered as a potentially novel approach for treating neurodegenera-
tive disorders [160, 183], although its role in neurodegenerative disorders remains unclear [11].
Even though autophagy may be initially induced as a neuroprotective response, due to
excessive, imbalanced induction or defects in completing degradation, it may also contribute
to neuronal atrophy, neurite degeneration, and cell death [19, 177]. It is noteworthy that the
failed attempt of autophagy at neuron survival has been closely associated with age-related
autophagy insufficiency and lysosomal aging [19]. In fact, several evidences recently suggest
a possible role for autophagic dysfunction in the pathogenesis of neurodegenerative diseases
[184]. Conversely, autophagy also has the ability to decrease the accumulation of toxic,
aggregate-prone proteins that cause neurodegeneration [11, 183]. As summarized in the
following paragraph, multiple studies provide proof of principle for the activation of autoph-
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agy as a therapy for neurodegenerative disease. To date, there are still very few reported clinical
results demonstrating that modulation of autophagy indeed represents an effective therapeu-
tic intervention for these devastating diseases [11].
HD disease is caused by a polyglutamine expansion mutation in the huntingtin protein (polyQ-
expanded Htt) that confers a toxic gain-of-function and causes the protein to become aggre-
gate-prone proteins, which are cleared by autophagy. It is noteworthy that upregulating this
process by Rapamycin attenuates their toxicity in various HD models [181, 185]. The autophagy
inducer Rapamycin or its analog CCI-779 has been reported to promote autophagic clearance
of polyQ-expanded Htt protein [178, 181, 186]. Likewise, Rapamycin increases the clearance
of α-synuclein and lessens the formation of aggregates (Lewy bodies) in neurons [179].
Rapamycin in combination with lithium showed a greater protection against neurodegenera-
tion in an HD fly model [185]. Interestingly, the disaccharide bilayer membrane-protector
Trehalose [187] accelerates the autophagic clearance of mutant Huntingtin and α-synuclein
through an mTOR-independent pathway [95]. However, in a combination of mTOR inhibitor,
Rapamycin Trehalose’s effect on autophagic activity increases, resulting in an additive effect
on the clearance of the above proteins [95]. Together these studies demonstrate that autophagy
upregulation and promotion of aggregation-prone protein degradation ameliorate neurode-
generative pathology, but conversely autophagy inhibition enhances the toxicity of these
proteins [184].
7. Autophagy modulators for treatment of other diseases
Similar to the details outlined above for neurodegenerative disorders, autophagy upregulation
may enhance the clearance of a range of infectious agents, including multidrug-resistant
(MDR) strains of Mycobacterium tuberculosis. In some cases, mouse models and preclinical data
have strengthened the protective role of autophagy against microbial infections, as summar-
ized in Table 5.
AR-12 induces autophagic clearance of Francisella tularensis from the human leukemic cell line
THP-1 macrophages [188] and Salmonella enterica serovar Typhimurium in murine macrophages,
both in vitro and in vivo [189]. Additionally, experimental findings underscore the importance
of host autophagy in orchestrating successful antimicrobial responses to Mycobacterium
tuberculosis during chemotherapy with Isoniazid and Pyrazinamide [190]. Likewise, the most
active form of vitamin D 1,25D3 may inhibit replication of human immunodeficiency virus
(HIV) in human macrophages through autophagy activation [191].
Based on these preclinical findings, researchers have raised the possibility that some antimyco-
bacterial chemotherapies already used in clinical for the treatment of infectious diseases anti-
infection effects, at least partially, via inducing autophagy. However, it is still unclear whether
those findings can be translated into the clinical treatment of certain infections [11]. Stimulation
of autophagy with Rapamycin reduces intracellular survival of mycobacteria in macrophages
[192].
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Drugs Effects
1,25D3 1α,25-dihydroxycholecalciferol inhibits HIV replication and mycobacterial growth [191].
AR-12 2-amino-N-4-5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl phenyl-acetamide inhibits
activity of phosphoinositide-dependent kinase-1 and promotes autophagic clearance of bacteria
in human and murine macrophages [188, 189].
Carbamazepine Induces antimicrobial autophagy through a mTOR-independent pathway controlled by cellular
depletion of myo-inositol [193].
Fluoxetine A selective serotonin reuptake inhibitor, enhances secretion of proinflammatory cytokine TNF-α
and induces autophagy in Mycobacterium tuberculosis–infected macrophages [194].
Gefitinib An inhibitor of the Epidermal Growth Factor Receptor (EGFR), activates autophagy, and
restricts growth of Mycobacterium tuberculosis in the lungs of infected mice [194].
Isoniazid or
pyrazinamide
Reduces Mycobacterium tuberculosis (Mtb)–induced proinflammatory responses by promoting
autophagy activation and phagosomal maturation in Mtb-infected host cells [190].
Nitozoxanide Nitazoxanide and its active metabolite Tizoxanide strongly stimulate autophagy and inhibit
mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis [195].
Nortriptyline Induces the formation of autophagosomes that progressively acidify over time and become
competent for Mycobacterium tuberculosis degradation in infected macrophages [196].
Prochlorperazine
edisylate
Modulates autophagy that correlates with delivery of Mycobacterium tuberculosis to lysosomes
leading to mycobacterial degradation [196].
Rapamycin Induces autophagy and suppresses intracellular survival of M. tuberculosis [192].
Statins Enhances autophagy and phagosome maturation leading to reduction the Mycobacterium
tuberculosis burden in human macrophages and in mice [197].
Valproic acid Stimulates autophagic killing of intracellular Mycobacterium tuberculosis within primary human
macrophages [193].
Table 5. Preclinical studies of the effects of autophagy activators on infectious diseases.
Remarkably, several FDA-approved drugs counter M. tuberculosis infection, possibly through
autophagy, which disrupts the host-pathogen equilibrium in favor of the host (see Table 5).
The antidepressants Fluoxetine [194] and Nortriptyline [196], the anticonvulsants Carbama-
zepine and Valproic acid, and the antipsychotic Prochlorperazine edisylate reveal relevant
antimycobacterial properties by targeting autophagy in the host (i.e., infected macrophages).
Notably, in mice infected with a highly virulent MDR-strain of Mycobacterium tuberculosis,
Carbamazepine reduces bacterial burden, improve lung pathology, and stimulate adaptive
immunity [193]. Furthermore, the tyrosine kinase inhibitor (Gefitinib) also activates autophagy
and suppress Mycobacterium tuberculosis in macrophages and, to some extent, in infected mice
[194]. Other autophagy-inducing candidate drugs attempting to Antituberculosis Host-
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Directed Therapy (HDT) include antiprotozoal drug Nitozoxanide [195] and cholesterol-
lowering drugs, i.e., Statin [197]. Together these findings support that autophagy enhancement
by repurposed drugs provides an easily implementable potential therapy for the treatment of
multidrug-resistant mycobacterial infection.
8. Promising future therapeutic strategies
8.1. The case of the pentacyclic triterpenoids, the working hypothesis
After decades of scientific discoveries and discussions [10, 198] the general agreement is that
autophagy associated cell-death is commonly linked to failure in either the fusion of autopha-
gosomes with lysosomes or in the digestion activity of autolysosomes [27, 198]. Whereas the
understanding of this process at the molecular level needs a deeper knowledge of the compe-
tition between its activation and inhibition pathways, autophagy has been explored as a
potential therapeutically target for treating several diseases [11, 14]. Consequently, the impact
of activating mitophagy on the condition of autophagy impairment is a noteworthy subject to
explore. A recent work has proposed that by modulating parallel damage in membranes of
mitochondria and lysosome, autophagy turns into a destructive process [12]. Comparative
analysis of the biological effects of two chemical isomers, i.e., pentacyclic triterpenoids
Betulinic and Oleanolic acids (BA and OA, respectively), Martins and colleagues showed that
the main differences between the activity of BA and OA is due to their efficiency in interacting
and damaging membranes [12] (see Figure 1). These triterpenoids are new promising drugs
with various pharmacological actions (anti-inflammatory, antiviral, antifungal, antimalarial,
among others), being easily extracted from plants [199]. So far, about 2167 patents for AB and
1018 for OA have been deposited.
Figure 1. Modulation of membrane damage provided insights into biological effects of triterpenoids in vitro (Figure
kindly supplied by Martins WK).
By comparing these triterpenoids, it was realized that the fate of autophagy may depend on
the extent of lysosomal and mitochondrial membrane damage. In case of OA, there is marked
Autophagy in Current Trends in Cellular Physiology and Pathology368
cytoplasmic vacuolization and mitochondria shrinkage with remarkable cellular recovery that
was intrinsically associated with autophagy activation. However, cell recovery failed upon
concomitant lysosome inhibition with CQ or Bafilomycin A1 [12]. Of note, the lysosomal
damage BA-mediated is per se capable of compromising autophagy, without any incremental
damage when lysosomal function was deeply altered by lysosomal inhibitors, such as CQ and
Bafilomycin A1.
BA and OA differ significantly on their ability to penetrate membranes, which appears to be
mainly related to the twisted backbone structure of OA, in contrast to the fully planar structure
of BA. Interestingly, this stronger efficiency in interacting and damaging membrane mimics
ascribed to BA correlates with a higher ability of disturbing mitochondrial and lysosomal
membranes of human keratinocytes [12]. The ability of BA to disturb the mitochondrial
membrane is in agreement with other published results [106, 200, 201]. For example, by
inhibiting the activity of steroyl-CoA-desaturase (SCD-1) BA may also directly and rapidly
impact on the saturation level of cardiolipin (CL), a specific mitochondrial phospholipid lipid
that has important structural and metabolic functions, and at the same time regulates mito-
chondria-dependent cell death [202]. Interestingly, thermodynamic analyses of Langmuir
monolayers and AFM study of Langmuir-Blodgett monolayers provide insights into the ability
of BA interacting with CL-enriched membranes. BA may orient nearly perpendicularly with
hydroxyl group toward water, which causes phase separation and changes the permeability
of CL film [203]. BA was also shown to disrupt membranes of human red blood cells (RBC) in
vitro, with release of calcein from the RBC ghosts in a way similar to Digitonin in membrane
permeabilization experiments [204].
Of note, the damage in lysosomal function caused by BA may not be explained by traditional
justifications (lack of lysosome acidification or neutralization of its internal pH). Otherwise,
BA disturbs lysosome’s membrane integrity that dramatically jeopardizes the lysosomal
function, leading to a lysosomal-mitochondrial axis of cellular stress that causes autophagy-
associated cell death [12]. Remarkably, in the survival of BA-challenged cells occurs sustained
formation of reactive oxygen species (ROS) inside nonfunctional lysosomes, which in the long-
term response leads to lipofuscinogenesis, genomic instability, and cell senescence [13]. Thus,
promotion of concomitant damage in mitochondrial and lysosomal membranes seems to be
an efficient strategy for inducing autophagy-associated cell death and cell aging.
The AB’s ability to promote parallel damage in lysosomes and mitochondria could be the
explication for the positive synergistic action of BA in different antitumor protocols including
radiation [205, 206], chemotherapy drugs, such as Cisplatin [207] and Vincristine [208].
Therefore, the possible increase of cell death potentially relates to the AB ability of suppressing
prosurvival autophagy. The knowledge of this premise at molecular level may contribute to
the development of new autophagy modulators.
Since 1995, BA has been considered as a highly promising anticancer drug showing remarkable
antitumor effects against several human tumors [106, 208–222]. In addition, in the last decade,
many studies have shown further effects that justify the expectation that triterpenes and
synthetic analogs are useful to treat cancer by several modes of action [223]. For example, BA
acid derivatives are under evaluation as chemotherapeutic agent against several types of
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human tumors in vitro and in vivo [152, 199, 223–235]. The synthetic analog of OA [2-cya-
no-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)] is currently under clinical Phase I study
(NCT00322140) for treating solid tumors and lymphoma [101]. Introduced in 2009, the new
semisynthetic candidate drug designated NVX-207 (3-acetyl-betulinic 2-amino-3-hydroxy-2-
hydroxymethyl-hi-ethyl propanoate) enhanced apoptosis-inducing activity and dramatically
enhanced solubility over BA [230]. However, limited solubility and often ultimately modest
efficacy have hampered the development of this class of compounds [230]. Thus, scientific
efforts focused on the elucidation of molecular mechanisms triggered by these triterpenoids,
attending the interests of the scientific community as well as of the pharmaceutical industry.
9. Perspectives for drug development
During the last decade, important progress was made in understanding the molecular basis
of autophagy uncovering its potential in anticancer therapies [105, 236, 237]. Because the
abrogation of autophagy via knockdown of autophagy-related molecules increases the
sensibility of therapy-resistant cancer cells to conventional cancer therapies, there has been
great interest in developing clinically relevant autophagy inhibitors [238]. As reviewed by Yang
and colleagues, multiple studies have shown that genetic knockdown of autophagy-related
genes (Atgs) or pharmacological inhibition of autophagy can effectively enhance tumor cell
death induced by diverse anticancer drugs in preclinical models [64].
Figure 2. Modulation of membrane damage provided insights into biological effects after PDT (Figure kindly supplied
by Martins WK).
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Photodynamic therapy (PDT) is a procedure that has applications in the selective eradication
of cancer where sites of tumor lesions are clearly delineated. It is a two- step process whereby
cells are first incubated with photosensitizers and then photoirradiated. This results in the
formation of singlet molecular oxygen and other reactive oxygen species (ROS) that can cause
photodamage at sites where the photosensitizing agent has localized [239]. Photosensitizers
found to be clinically useful, showing affinity for the endoplasmic reticulum, mitochondria,
lysosomes, or combinations of these sites [240]. The induction of cell death triggered by
apoptosis and/or autophagy in photosensitized cells is a common outcome of PDT [239–242].
Therefore, the photosensitizers are drugs that are used to treat a series of different diseases.
Our group has addressed the concept of parallel photodamage in mitochondria and lysosome
with the consequent induction of cell death and senescence after PDT (Figure 2). In near future,
we will exploit the possible use of this concept in the development of new photosensitizers
targeting autophagy as cell death mechanism.
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